STOCKHOLM--(BUSINESS WIRE)--Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that the first patient has been randomized in the phase II study (anaGO) to evaluate efficacy and safety of Kineret® (anakinra) in the treatment of acute gout.
The purpose of the study is to evaluate pain relief in people with acute gout who cannot take or have not previously responded to non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine. The anaGO study is a randomized, double-blind, multicenter study being conducted in North America studying two dose levels of anakinra (s.c.) in comparison to intramuscular triamcinolone. In total 159 individuals are planned to be randomized in the study.
“There is a persistent and significant unmet medical need for resolving pain in people affected by acute gout, and there is a strong scientific rationale for investigating the safety and efficacy of anakinra in this disease. Therefore we are very excited to have the first patient randomized in this important Phase II study. We look forward to working with the study sites, and plan to complete enrollment by the second half of 2017,” says Milan Zdravkovic, Senior Vice President, Head of Research & Development at Sobi.
Read more: http://www.businesswire.com/news/home/20170111005068/en/Patient-Randomized-Phase-II-Study-Evaluating-Safety